机器人对比腹腔镜结肠切除术治疗I-III期结肠癌:肿瘤学与长期生存结局
基于美国国家癌症数据库(2010-2012)15112例I-III期结肠腺癌患者,比较机器人(5.1%)与腹腔镜(94.9%)部分或全结肠切除术的肿瘤学与生存结局。倾向评分匹配后,机器人组在II期(5年生存率66.9% vs 56.8%,p=0.0189)和III期(78.6% vs 64.9%,p=0.0241)生存更优,肿瘤学结局与腹腔镜相当。
要点
- 机器人组与腹腔镜组淋巴结检出数无差异(p=0.6200),切缘阳性率无差异(OR 1.09,p=0.649)
- 多因素分析显示机器人组死亡风险改善(HR 0.79,p=0.027)
- 倾向评分匹配后机器人组II期和III期结肠癌5年生存率均优于腹腔镜组
核心结论
- 机器人部分或全结肠切除术治疗I-III期结肠癌的肿瘤学结局与腹腔镜相当。
- 相对腹腔镜,机器人入路似乎提供改善的长期生存。
研究设计与样本
- 回顾性队列研究,基于美国国家癌症数据库(2010-2012)数据。
- 纳入I-III期结肠腺癌接受机器人或腹腔镜部分或全结肠切除术的患者,共15112例,机器人组765例(5.1%),腹腔镜组14347例(94.9%)。
- 采用线性回归和逻辑回归比较淋巴结检出、手术切缘和生存,并用倾向评分匹配创建可比队列比较生存函数。
主要发现
- 机器人组中转率10.6%(n=765),腹腔镜组中转率15.1%(n=14347)。
- 机器人入路与西班牙裔种族(p=0.009)、私人保险(p=0.001)和较早分期(p=0.028)相关。
- 淋巴结检出数无差异(p=0.6200),阴性手术切缘无差异(p=0.6700)。
- 多因素分析中机器人入路与改善的死亡风险相关(HR 0.79,p=0.027)。
- 线性回归显示淋巴结检出无差异(-0.39,p=0.285);逻辑回归显示切缘阳性率无差异(OR 1.09,p=0.649)。
临床怎么用
- 对于I-III期结肠癌,机器人结肠切除术可作为腹腔镜的替代选择,肿瘤学安全性相当。
- 机器人入路可能为II期和III期结肠癌患者带来长期生存获益,但需结合患者具体情况和医疗资源个体化决策。
局限性
- 回顾性数据库研究,存在选择偏倚可能,尽管使用了倾向评分匹配。
- 机器人组样本量较小(765例),可能影响亚组分析的效力。
- 未报告长期生存的详细多因素校正结果,仅报告倾向评分匹配后的生存比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While short-term data suggest that robotic resections are safe for oncologic operations, long-term outcomes remain uncertain. This study evaluates the impact of robotic and laparoscopic approaches on oncologic and survival outcomes in partial and total colectomies for colon cancer. METHODS: The US National Cancer Database (2010-2012) was reviewed for patients with stage I-III adenocarcinoma of the colon, who underwent robotic and laparoscopic partial or total colectomies. Lymph node retrieval, surgical margins, and survival were compared between surgical approaches with linear and logistic regressions. Propensity score matching was then used to create comparable laparoscopic and robotic cohorts and compare survivor functions. RESULTS: Of 15,112 patients, 5.1% underwent robotic approaches (n = 765, conversion rate 10.6%), and 94.9% laparoscopic (n = 14,347, conversion rate 15.1%). Robotic approach was associated with Hispanic race (p = 0.009), private insurance (p = 0.001), and earlier stage (p = 0.028). There was no difference in number of lymph nodes retrieved (p = 0.6200) or negative surgical margins (p = 0.6700). In multivariate analysis, robotic approaches were associated with an improved hazard of mortality (HR 0.79, p = 0.027). Linear regression found no difference in lymph node retrieval (- 0.39, p = 0.285). Logistic regression found no difference in rates of positive margins (OR 1.09, p = 0.649). After propensity score matching, robotic approaches were associated with improved survival in stage II (5YS 66.9% vs. 56.8%, p = 0.0189) and III disease (5YS 78.6% vs. 64.9%, p = 0.0241). CONCLUSION: Robotic approaches to partial and total colectomies for stage I-III colon cancer offer comparable oncologic outcomes as laparoscopic approaches. Relative to laparoscopic approaches, robotic approaches appear to offer improved long-term survival.
引用
- Mirkin KA, Kulaylat AS, Hollenbeak CS, et al. Robotic versus laparoscopic colectomy for stage I-III colon cancer: oncologic and long-term survival outcomes. Surg Endosc. 2017. PMID: 29273877. doi:10.1007/s00464-017-5999-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。